Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/121721
Title: | Allogeneic platelet-rich plasma for knee osteoarthritis in patients with primary immune thrombocytopenia : a randomized clinical trial |
Authors: | Zhu, Xiaohang Zhao, Lingying Riva, Nicoletta Yu, Ziqiang Jiang, Miao Zhou, Feng Gatt, Alexander Giannoudis, Peter V. Guo, Jiong Jiong |
Keywords: | Blood platelet disorders Thrombocytopenia Osteoarthritis Clinical trials |
Issue Date: | 2024 |
Publisher: | Cell Press |
Citation: | Zhu, X., Zhao, L., Riva, N., Yu, Z., Jiong, M., Zhou, F., Gatt, A., Giannoudis, P. V. & Guo, J. J. (2024). Allogeneic platelet-rich plasma for knee osteoarthritis in patients with primary immune thrombocytopenia : a randomized clinical trial. iScience, 27(5), 109664. |
Abstract: | The treatment of painful KOA in adult patients with ITP has not been well studied yet. We conducted a prospective, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of intra-articular allogeneic PRP injections on symptoms and joint structure in patients with KOA and ITP. 80 participants were randomly allocated in a 1:1 ratio to allogeneic PRP group or saline group. The primary outcome was the WOMAC total score at 12 months post-injection. The number of patients in each group who achieved MCID of primary outcome showed a statistically significant difference only at 3-month (27/39 vs. 5/39, p = 0.001) and 6-month (15/39 vs. 3/38, p = 0.032). The difference in WOMAC total score exceeded the MCID only at 3 month (mean difference of -15.1 [95% CI -20.7 to -9.5], p < 0.001). Results suggest that allogeneic PRP was superior to placebo only with respect to symptoms at 3-month of follow-up. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/121721 |
Appears in Collections: | Scholarly Works - FacM&SPat |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2- Zhu 2024.pdf | 3.74 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.